Herbal Drugs Used in the Management of Alzheimer’s Disease: A Comprehensive Review of Phyto-Therapeutic Approaches, Mechanisms and Future Perspectives

Authors

  • Girish Kumar Yadav Department of Pharmacy, IEC University, Baddi, Himachal Pradesh, India
  • Amarjeet Singh Department of Pharmacy, IEC University, Baddi, Himachal Pradesh, India
  • Rambabu Sharma Department of Pharmacy, Himalayan Institute of Pharmacy, Kala-Amb, Himachal Pradesh, India

Abstract

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder and the most common cause of dementia, characterized by progressive impairment of memory, cognition, behavior and activities of daily living. Its pathogenesis is multifactorial and involves amyloid-β (Aβ) aggregation, hyperphosphorylation of tau protein, cholinergic dysfunction, oxidative stress, mitochondrial impairment, neuroinflammation, synaptic dysfunction and neuronal loss.¹–⁴ Although conventional pharmacotherapy includes acetylcholinesterase inhibitors, memantine and, more recently, disease-modifying anti-amyloid antibodies, limitations such as modest symptomatic efficacy, adverse effects, treatment burden, cost and the need for careful patient selection continue to stimulate research into complementary therapeutic approaches.⁵–⁷ Medicinal plants contain diverse bioactive compounds capable of acting simultaneously on several pathological pathways. Important herbal candidates investigated in AD include Ginkgo biloba, Bacopa monnieri, Withania somnifera, Curcuma longa, Crocus sativus, Salvia officinalis, Melissa officinalis, Panax ginseng, Centella asiatica, Huperzia serrata, Nigella sativa and Camellia sinensis.⁸–¹² Their reported activities include acetylcholinesterase inhibition, antioxidant and anti-inflammatory effects, modulation of amyloid and tau pathology, mitochondrial protection, enhancement of neurotrophic signaling and improvement of synaptic plasticity. Recent systematic reviews of human studies suggest that Ginkgo biloba, Crocus sativus, Salvia officinalis and Melissa officinalis have produced encouraging cognitive or behavioral findings, although study quality, formulations, doses and treatment duration vary substantially.¹³,¹⁴ Future development should focus on standardized phytopharmaceutical preparations, pharmacokinetic optimization, advanced drug-delivery systems, validated biomarkers, well-designed randomized clinical trials and rational combination therapy. Herbal medicines therefore represent a promising research avenue, but current evidence does not justify considering them universally equivalent or superior to established pharmacological treatment.

Keywords: Alzheimer’s disease; herbal drugs; curcumin; Ginkgo biloba; amyloid-β; tau; cognitive impairment.

Keywords:

Alzheimer’s disease, herbal drugs, curcumin, Ginkgo biloba, amyloid-β, tau, cognitive impairment

DOI

https://doi.org/10.22270/jddt.v16i11.8067

Author Biographies

Girish Kumar Yadav , Department of Pharmacy, IEC University, Baddi, Himachal Pradesh, India

Department of Pharmacy, IEC University, Baddi, Himachal Pradesh, India

Amarjeet Singh, Department of Pharmacy, IEC University, Baddi, Himachal Pradesh, India

Department of Pharmacy, IEC University, Baddi, Himachal Pradesh, India

Rambabu Sharma, Department of Pharmacy, Himalayan Institute of Pharmacy, Kala-Amb, Himachal Pradesh, India

Department of Pharmacy, Himalayan Institute of Pharmacy, Kala-Amb, Himachal Pradesh, India

References

1. World Health Organization. Dementia. Geneva: WHO; 2026.

2. Kumar A, Dogra S, Vashist HR, Sharma RB. Parkinson’s disease, cause, progression and treatment. Innovat International Journal of Medical & Pharmaceutical Sciences. 2019;4(4):1-6.

3. Kumar A, Singh A, Ekavali. A review on Alzheimer’s disease pathophysiology and its management: an update. Pharmacol Rep. 2015;67(2):195-203. https://doi.org/10.1016/j.pharep.2014.09.004 PMid:25712639

4. Chen XQ, Mobley WC. Alzheimer disease pathogenesis: insights from molecular and cellular biology. J Cell Biol. 2019;218(10):3359-3381. https://doi.org/10.3389/fnins.2019.00659 PMid:31293377 PMCid:PMC6598402

5. Hampel H, Hardy J, Blennow K, Chen C, Perry G, Kim SI, et al. The amyloid-β pathway in Alzheimer’s disease. Mol Psychiatry. 2021;26:5481-5503. https://doi.org/10.1038/s41380-021-01249-0 PMid:34456336 PMCid:PMC8758495

6. Unveiling the multifaceted pathogenesis and therapeutic drugs of Alzheimer’s disease: a comprehensive review. Heliyon. 2024;10. https://doi.org/10.1016/j.heliyon.2024.e39217 PMid:39629139 PMCid:PMC11612466

7. Cummings J, Lee G, Zhong K, Fonseca J, Taghva K. Alzheimer’s disease drug development pipeline: 2023. Alzheimers Dement (N Y). 2023;9(2).

8. U.S. Food and Drug Administration. Drug trials snapshots: LEQEMBI (lecanemab-irmb). Silver Spring: FDA.

9. Kim J, Al Jerdi S, MacDonald ME, Triggle DJ. Alzheimer’s disease and its treatment-yesterday, today, and tomorrow. Front Pharmacol. 2024;15:1399121. https://doi.org/10.3389/fphar.2024.1399121 PMid:38868666 PMCid:PMC11167451

10. Advances in bioactive compounds from plants and their applications in Alzheimer’s disease. Int J Mol Sci. 2026;16:7.

11. Sharma D, Vashist H, Sharma RB. Pharmacological aspects on Murraya koenigii-a review. Eur J Biomed Pharm Sci. 2015;2:664-668.

12. Alzheimer A. Über eine eigenartige Erkrankung der Hirnrinde. Allgemeine Zeitschrift für Psychiatrie. 1907;64:146-148.

13. Poonam P, Vashist HR, Sharma RB, Dorga S. Role of flavonoids as an anti-inflammatory agent. Innov. Int. J. Med. Pharm. Sci. 2019;4(3):1-6.

14. Yiannopoulou KG, Papageorgiou SG. Current and future treatments in Alzheimer disease: an update. Journal of central nervous system disease. 2020 Feb;12:1179573520907397. https://doi.org/10.1177/1179573520907397 PMid:32165850 PMCid:PMC7050025

15. Kumar A, Singh A, Ekavali F. A review on Alzheimer’s disease pathophysiology and its management: an update. Pharmacological reports. 2015 Mar;67(2):195-203. https://doi.org/10.1016/j.pharep.2014.09.004 PMid:25712639

16. National Institute on Aging. What happens to the brain in Alzheimer’s disease? Bethesda: National Institutes of Health; 2026.

17. Ahmadi S, Khaledi S, Ahmadi K, Hassanzadeh K. Amyloid beta in Alzheimer’s disease: mechanisms, biomarker potential, and therapeutic targets. CNS Neuroscience & Therapeutics. 2025 Dec;31(12):e70688. https://doi.org/10.1002/cns.70688 PMid:41363055 PMCid:PMC12686972

18. Li C, Fu M, Berg K, Wallach J, Ling K, Wei R, Shi L, Ross J, Guan X. Efficacy measures used in Alzheimer disease clinical trials between 2015 and 2025: a systematic review. Neurology. 2026;107(4):e218373. https://doi.org/10.1212/WNL.0000000000218373 PMid:42492033 PMCid:PMC13445500

19. Recent updates on Alzheimer’s disease: pathogenesis, pathophysiology, molecular approaches and natural bioactive compounds used in contemporary time to alleviate disease. Curr Neuropharmacol. 2025.

20. Oxidative stress in Alzheimer’s disease: the shortcomings of antioxidant therapies. J Alzheimers Dis. 2024;101.

21. U.S. Food and Drug Administration. Drug trials snapshots: KISUNLA (donanemab-azbt). Silver Spring: FDA; 2024.

22. Bolshakov AP, Gerasimov K, Dobryakova YV. Alzheimer’s disease: an attempt of total recall. J Alzheimers Dis. 2024;101(4):1043-1061. https://doi.org/10.3233/JAD-240620 PMid:39269841

23. Phytoactive drugs used in the treatment of Alzheimer’s disease and dementia. Naunyn Schmiedebergs Arch Pharmacol. 2024;397(11):8633-8649. https://doi.org/10.1007/s00210-024-03243-z PMid:38940847

24. Review of pharmacotherapeutic targets in Alzheimer’s disease and its management using traditional medicinal plants. Degener Neurol Neuromuscul Dis. 2024;14:47-74. https://doi.org/10.2147/DNND.S452009 PMid:38784601 PMCid:PMC11114142

25. Liu M, Li T, Liang H, Zhong P. Herbal medicines in Alzheimer’s disease and the involvement of gut microbiota. Front Pharmacol. 2024;15:1416502. https://doi.org/10.3389/fphar.2024.1416502 PMid:39081953 PMCid:PMC11286407

26. Silva RB, Stein C, de Araujo BC, de Oliveira Cruz Latorraca C, Cruz CM, de Toledo IP, Guedes de Almeida MM, do Carmo Silva Parreira P, Pacheco RL, Colpani V, Riera R. Efficacy and safety of transcranial Direct Current Stimulation (tDCS) in Alzheimer’s disease: systematic review and meta-analysis. BMC Neurology. 2026. https://doi.org/10.1186/s12883-026-05330-5

27. National Institute on Aging. Alzheimer’s disease: causes and risk factors. Bethesda: NIH; 2026.

28. A comprehensive systematic review of human trials investigating herbal treatments for Alzheimer’s disease and dementia. Neurol Sci. 2026. doi:10.1017/neu.2026.10085. https://doi.org/10.1017/neu.2026.10085 PMid:42100836 PMCid:PMC13280518

29. Bayo Jimenez MT, Rivas-García L, Sánchez-González C, Grosso G, Lipari V, Vera-Ramírez L, et al. Natural products in Alzheimer’s disease: a systematic review of clinical trials and underlying molecular mechanisms. Int J Mol Sci. 2025;26(21):10631. https://doi.org/10.3390/ijms262110631 PMid:41226670 PMCid:PMC12609458

30. National Institute on Aging. What happens to the brain in Alzheimer’s disease? Bethesda: National Institutes of Health; 2026.

31. Beder N, et al. Involvement of inflammasomes in the pathogenesis of Alzheimer’s disease. J Alzheimers Dis. 2024;102(1):11-29. https://doi.org/10.1177/13872877241283677 PMid:39497307

32. The central role of neuronal cell death in Alzheimer’s disease pathobiology. 2026.

33. Liu M, Li T, Liang H, Zhong P. Herbal medicines in Alzheimer’s disease and the involvement of gut microbiota. Front Pharmacol. 2024;15:1416502. https://doi.org/10.3389/fphar.2024.1416502 PMid:39081953 PMCid:PMC11286407

34. Clinical practice guidelines for dementia: recommendations for cholinesterase inhibitors and memantine. 2025.

35. Toward a unified framework in molecular neurobiology of Alzheimer’s disease: revisiting the pathophysiological hypotheses. 2026.

36. Morató X, Tartari JP, Pytel V, Boada M. Pharmacodynamic and clinical effects of Ginkgo biloba extract EGb 761 and its phytochemical components in Alzheimer’s disease. J Alzheimers Dis. 2024;101(S1). https://doi.org/10.3233/JAD-231372 PMid:39422946

37. Comprehensive insights into pathophysiology of Alzheimer’s disease: herbal approaches for mitigating neurodegeneration. Curr Neuropharmacol. 2024.

38. Pase MP, Kean J, Sarris J, Neale C, Scholey AB, Stough C. Use of Bacopa monnieri in the treatment of dementia due to Alzheimer disease: systematic review of randomized controlled trials. J Altern Complement Med. 2022;28.

39. Curcumin in Alzheimer’s disease: from mechanistic insights to translational challenges and emerging curcuminoid strategies. 2026.

40. Kumar N, Kour M, Sharma S, Kumar D. Therapeutic potential of Withania somnifera in alleviating neurodegenerative diseases. Proceedings of the Indian National Science Academy. 2026 Sep 16:1-4. https://doi.org/10.1007/s43538-026-00918-4

41. Curcumin and cognitive function: a systematic review of the effects of curcumin on adults with and without neurocognitive disorders. 2024.

42. Han S, Cao Y, Wu X, Xu J, Nie Z, Qiu Y. New horizons for the study of saffron (Crocus sativus L.) and its active ingredients in the management of neurological and psychiatric disorders: a systematic review of clinical evidence and mechanisms. Phytother Res. 2024;38(5):2276-2302. https://doi.org/10.1002/ptr.8110 PMid:38424688

43. Akhondzadeh S, Noroozian M, Mohammadi M, Ohadinia S, Jamshidi AH, Khani M. Salvia officinalis extract in the treatment of patients with mild to moderate Alzheimer’s disease: a double blind, randomized and placebo-controlled trial. J Clin Pharm Ther. 2003;28(1):53-59. https://doi.org/10.1046/j.1365-2710.2003.00463.x PMid:12605619

44. Advances in bioactive compounds from plants and their applications in Alzheimer’s disease. Int J Mol Sci. 2026;16(1):7.

45. Sharma RB, Sharma R, Bora KS. Role of medicinal plants for the treatment of Alzheimer’s disease. Journal of Pharmaceutical Research International. 2021 Dec 18;33(59B):422-431. https://doi.org/10.9734/jpri/2021/v33i59B34399

46. Singh BK, Babu SR. Role of medicinal plants in the management of brain disorders: a review update. Plant Cell Biotechnology and Molecular Biology. 2021 Oct 25;22(59-60):95-104.

47. Little JT, Walsh S, Aisen PS. An update on huperzine A as a treatment for Alzheimer’s disease. Expert Opin Investig Drugs. 2008;17(2):209-215. https://doi.org/10.1517/13543784.17.2.209 PMid:18230054

48. Wang BS, Wang H, Wei ZH, Song YY, Zhang L, Chen HZ. Efficacy and safety of natural acetylcholinesterase inhibitor huperzine A in the treatment of Alzheimer’s disease: an updated meta-analysis. J Neural Transm (Vienna). 2009;116(4):457-465. https://doi.org/10.1007/s00702-009-0189-x PMid:19221692

49. Di Bona D, Plaia A, Giacalone A, Di Marco L, Rizzo S, Di Gesaro V, et al. Dissecting the potential roles of Nigella sativa and its constituent thymoquinone on the prevention and on the progression of Alzheimer’s disease. Front Aging Neurosci. 2018;10:16. https://doi.org/10.3389/fnagi.2018.00016 PMid:29479315 PMCid:PMC5811465

50. Zhang S, Zhu Q, Chen JY, OuYang D, Lu JH. The pharmacological activity of epigallocatechin-3-gallate (EGCG) on Alzheimer’s disease animal model: a systematic review. Phytomedicine. 2020;79:153316. https://doi.org/10.1016/j.phymed.2020.153316 PMid:32942205

51. AlNasser MN, Alboraiy G, Alsowig EM, Alqattan F. Cholinesterase inhibitors from plants and their potential in Alzheimer’s treatment: systematic review. Brain Sci. 2025;15(2):215. https://doi.org/10.3390/brainsci15020215 PMid:40002547 PMCid:PMC11852592

52. De Oliveira J, et al. The emerging role of nutraceuticals and phytochemicals in the prevention and treatment of Alzheimer’s disease. Curr Neuropharmacol. 2020;18(7):624-638.

53. Effect of natural plant products on Alzheimer’s disease. Curr Alzheimer Res. 2023.

54. Patel SS, Raghuwanshi R, Masood M, Acharya A, Jain SK. Medicinal plants with acetylcholinesterase inhibitory activity. Rev Neurosci. 2018;29(5):491-529. https://doi.org/10.1515/revneuro-2017-0054 PMid:29303784

55. Anand P, Singh B. A review on cholinesterase inhibitors for Alzheimer’s disease. Arch Pharm Res. 2013;36(4):375-399. https://doi.org/10.1007/s12272-013-0036-3 PMid:23435942

56. Small GW, Siddarth P, Li Z, Miller KJ, Ercoli LM, Emerson ND, et al. Memory and brain amyloid and tau effects of a bioavailable form of curcumin in non-demented adults: a double-blind, placebo-controlled 18-month trial. Am J Geriatr Psychiatry. 2018;26(3):266-277. https://doi.org/10.1016/j.jagp.2017.10.010 PMid:29246725 PMCid:PMC13271191

57. Nelson KM, Dahlin JL, Bisson J, Graham J, Pauli GF, Walters MA. The essential medicinal chemistry of curcumin. J Med Chem. 2017;60(5):1620-1637. https://doi.org/10.1021/acs.jmedchem.6b00975 PMid:28074653

58. Posadzki P, Watson L, Ernst E. Contamination and adulteration of herbal medicinal products (HMPs): an overview of systematic reviews. Eur J Clin Pharmacol. 2013;69(3):295-307. https://doi.org/10.1007/s00228-012-1353-z PMid:22843016

59. Kaczmarek-Kryszak KA, Dobrzyńska M, Banaszak M, Drymała-Czyż S. A comprehensive systematic review of human trials investigating herbal treatments for Alzheimer’s disease and dementia. Acta Neuropsychiatr. 2026;38:e42:1-30. doi:10.1017/neu.2026.10085. Cambridge University Press https://doi.org/10.1017/neu.2026.10085 PMid:42100836 PMCid:PMC13280518

60. Bayo Jimenez MT, Rivas-García L, Sánchez-González C, Grosso G, Lipari V, Vera-Ramírez L, et al. Natural products in Alzheimer’s disease: a systematic review of clinical trials and underlying molecular mechanisms. Int J Mol Sci. 2025;26(21):10631. https://doi.org/10.3390/ijms262110631 PMid:41226670 PMCid:PMC12609458

61. World Health Organization. Quality control methods for herbal materials. Geneva: World Health Organization; 2011.

62. European Medicines Agency. Guideline on specifications: test procedures and acceptance criteria for herbal substances, herbal preparations and herbal medicinal products/traditional herbal medicinal products. Revision 3. EMA/HMPC/CHMP/CVMP/162241/2005 Rev. 3. Amsterdam: European Medicines Agency; 2022.

63. Xie P, Chen S, Liang YZ, Wang X, Tian R, Upton R. Chromatographic fingerprint analysis-a rational approach for quality assessment of traditional Chinese herbal medicine. J Chromatogr A. 2006;1112(1-2):171-180. https://doi.org/10.1016/j.chroma.2005.12.091 PMid:16472540

64. Kamath AP, Nayak PG, John J, Mutalik S, Balaraman AK, Krishnadas N. Revolutionizing neurotherapeutics: nanocarriers unveiling the potential of phytochemicals in Alzheimer’s disease. Neuropharmacology. 2024;259:110096.. https://doi.org/10.1016/j.neuropharm.2024.110096 PMid:39084596

65. Youssef B, Ibrahim EA, Moselhy SS, ElShebiney S, et al. Phytochemical based on nanoparticles for neurodegenerative alzheimer disease management: update review. Nanoscale Res Lett. 2025;20(1):176. https://doi.org/10.1186/s11671-025-04356-x PMid:41062840 PMCid:PMC12508342

66. Paramanick D, et al. Neuroprotective effect of phytoconstituents via nanotechnology for treatment of Alzheimer diseases. J Control Release. 2022;351:638-655. https://doi.org/10.1016/j.jconrel.2022.09.058 PMid:36191675

67. Hampel H, Cummings J, Blennow K, Gao P, Jack CR Jr, Vergallo A, et al. Developing the ATX(N) classification for use across the Alzheimer disease continuum. Nat Rev Neurol. 2021;17(9):580-589. https://doi.org/10.1038/s41582-021-00520-w PMid:34239130

68. Teunissen CE, et al. Plasma p-tau immunoassays in clinical research for Alzheimer’s disease. Alzheimers Dement. 2025;21(1):e14397. https://doi.org/10.1002/alz.14397 PMid:39625101 PMCid:PMC11977406

Published

2026-11-15
Statistics
Abstract Display: 0
PDF Downloads: 0
PDF Downloads: 0

How to Cite

1.
Yadav GK, Singh A, Sharma R. Herbal Drugs Used in the Management of Alzheimer’s Disease: A Comprehensive Review of Phyto-Therapeutic Approaches, Mechanisms and Future Perspectives. J. Drug Delivery Ther. [Internet]. 2026 Nov. 15 [cited 2026 Nov. 16];16(11):100-9. Available from: https://www.jddtonline.info/index.php/jddt/article/view/8067

How to Cite

1.
Yadav GK, Singh A, Sharma R. Herbal Drugs Used in the Management of Alzheimer’s Disease: A Comprehensive Review of Phyto-Therapeutic Approaches, Mechanisms and Future Perspectives. J. Drug Delivery Ther. [Internet]. 2026 Nov. 15 [cited 2026 Nov. 16];16(11):100-9. Available from: https://www.jddtonline.info/index.php/jddt/article/view/8067